Hongbin Li

This inventor holds 22 USPTO granted patents and 6 published patent applications and 10 EPO patents. Top assignees: Forma Therapeutics, Inc., Valo Health, Inc., H. Lundbeck A/s. Active years: 2013-2025.

USPTO Granted Patents = 22 (Patent Applications = 6)

% Patents Active = 63.6

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 8.4

ph-index = 3

Forward Citations = 40(Granted Patents)

Location History:

Madson, CT (US) (2015)
Watertown, MA (US) (2019 - 2021)
Madison, CT (US) (2013 - 2023)
Newtown, CT (US) (2022 - 2023)

Company Filing History:

14 out of 125

Forma Therapeutics, Inc.

Valo Early Discovery, Inc.

patents

Years Active: 2013-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378242 - Inhibiting CREB binding protein (CBP) (2025-08-05),

2. 12351577 - Inhibiting cyclic AMP-responsive element-binding protein (CREB) (2025-07-08),

3. 12252490 - Inhibiting deubiquitinase USP25 and USP28 (2025-03-18),

4. 12162888 - Carboxamides as ubiquitin-specific protease inhibitors (2024-12-10),

5. 11814386 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2023-11-14),

6. 11787803 - Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors (2023-10-17),

7. 11535618 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2022-12-27),

8. 11524966 - Carboxamides as ubiquitin-specific protease inhibitors (2022-12-13),

9. 11325917 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors (2022-05-10),

10. 11292791 - Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors (2022-04-05),

11. 11254674 - Inhibiting CREB binding protein (CBP) (2022-02-22),

12. 10995078 - Compounds and compositions for inhibition of FASN (2021-05-04),

13. 10913753 - Thienopyridine carboxamides as ubiquitin-specific protease inhibitors (2021-02-09),

14. 10889592 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors (2021-01-12),

15. 10870648 - Inhibiting CREB binding protein (CBP) (2020-12-22),

Title: The Innovative Journey of Hongbin Li

Introduction:

Hongbin Li, a talented inventor based in Madison, CT, has made significant contributions to the field of technology through his groundbreaking innovations and patents.

Latest Patents:

Hongbin Li's latest patents include cutting-edge technologies in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his versatility and forward-thinking approach.

Career Highlights:

With over two decades of experience in the tech industry, Hongbin Li has held key roles in various renowned companies, leading research and development teams to create pioneering solutions that have shaped the industry.

Collaborations:

Throughout his career, Hongbin Li has collaborated with top research institutions, universities, and leading tech companies to drive innovation and bring revolutionary ideas to life. His collaborative spirit has been instrumental in the success of many projects.

Conclusion:

In conclusion, Hongbin Li's passion for innovation, coupled with his dedication to pushing the boundaries of technology, has established him as a prominent figure in the world of inventions. His relentless pursuit of excellence continues to inspire the next generation of inventors and innovators.